Evercore ISI Group downgrades Legend Biotech to In-Line from Outperform, sets price target at $20

Evercore ISI Group downgraded Legend Biotech to In-Line from Outperform, setting a $20 price target, implying 14.3% upside from the Nov 13 close of $17.50. Recent analyst notes on the company have price targets ranging from $25 to $61.

Original reporting
Published Nov 16, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evercore ISI Group downgrades Legend Biotech to In-Line from Outperform, sets price target at $20 — source image
Decision brief

The 30-second read

$LEGNBearishLow
01

Why it matters

The downgrade reflects concerns about near‑term growth prospects, potentially prompting short sellers.

02

Market read

Analyst rating changes are a common catalyst for price movement in small‑cap biotech stocks.

03

What to watch

Potential upcoming clinical trial data could offset the downgrade if results are positive.

Relevance 5/10Novelty 5/10Timing: today

Background

Legend Biotech is a U.S.-listed biotech company focused on oncology therapies.

Company-level read

Ticker impact

$LEGNBearishMedium confidence
Context

Evercore ISI Group downgraded Legend Biotech to In-Line from Outperform and set a $20 price target.

Expected impact

likely downward pressure as investors price in the downgrade

Evidence & confidence

Downgrades typically lead to short-term sell pressure, especially for a small‑cap biotech.

Market effects

May weigh on other small‑cap biotech stocks as analysts reassess sector risk.

Limited to U.S. biotech investors.

Minimal global impact.

Counterpoint

Some investors may view the $20 target as a buying opportunity if they believe the downgrade is overly cautious.

Key entities

  • Evercore ISI Group

    Equity research firm issuing the downgrade.

Related articles

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.

$LEGNMedAI 8/10

Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%

Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.